A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)

NCT05063162 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

113

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)

Interventions

DRUG: Rozanolixizumab
OTHER: Placebo

Sponsor

UCB Biopharma SRL